{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:42:27Z","timestamp":1792078947990,"version":"4.4.0"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1001\/jamadermatol.2020.1587","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T16:06:38Z","timestamp":1592409998000},"page":"891","source":"Crossref","is-referenced-by-count":108,"title":["Association Between Medication Use and Bullous Pemphigoid"],"prefix":"10.1001","volume":"156","author":[{"given":"Sian-De","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ti","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"},{"name":"Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"},{"name":"Department of Dermatology, Xiamen Chang Gung Memorial Hospital, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chi","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"},{"name":"Department of Dermatology, Xiamen Chang Gung Memorial Hospital, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9863","key":"doi200031r1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases.","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"doi200031r2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.autrev.2017.03.010","article-title":"Bullous pemphigoid.","volume":"16","author":"Bagci","year":"2017","journal-title":"Autoimmun Rev"},{"key":"doi200031r3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid.","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"doi200031r4","first-page":"1077","article-title":"Diagnosis of autoimmune bullous diseases.","volume":"16","author":"van Beek","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"doi200031r5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2019.03.091","article-title":"Bullous pemphigoid and neuropsychiatric medications: an influence of drugs or of underlying conditions?","author":"Kridin","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"doi200031r6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/archdermatol.2010.322","article-title":"The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study.","volume":"146","author":"Taghipour","year":"2010","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi200031r7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions.","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol"},{"issue":"4","key":"doi200031r8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study.","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi200031r9","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-4632.2009.04345.x","article-title":"Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania.","volume":"49","author":"Baican","year":"2010","journal-title":"Int J Dermatol"},{"issue":"12","key":"doi200031r10","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1365-4632.2004.02292.x","article-title":"Spectrum of autoimmune bullous diseases in Kuwait.","volume":"43","author":"Nanda","year":"2004","journal-title":"Int J Dermatol"},{"issue":"5","key":"doi200031r11","first-page":"434","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany.","volume":"7","author":"Bertram","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"doi200031r12","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France.","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi200031r13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archderm.131.8.957","article-title":"Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany.","volume":"131","author":"Zillikens","year":"1995","journal-title":"Arch Dermatol"},{"issue":"2","key":"doi200031r14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","article-title":"Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland.","volume":"153","author":"Gudi","year":"2005","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi200031r15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes.","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"7662","key":"doi200031r16","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study.","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"doi200031r17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations.","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"doi200031r18","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jaad.2014.07.052","article-title":"A population-based study of the association between bullous pemphigoid and neurologic disorders.","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"doi200031r19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature.","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi200031r20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2133.2011.10386.x","article-title":"Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study.","volume":"165","author":"Chen","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi200031r21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","article-title":"The associations between bullous pemphigoid and drug use: a UK case-control study.","volume":"149","author":"Lloyd-Lavery","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"10","key":"doi200031r22","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients.","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi200031r23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2019.107515","article-title":"The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: a retrospective cohort study.","volume":"34","author":"Guo","year":"2020","journal-title":"J Diabetes Complications"},{"issue":"5","key":"doi200031r24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-4362.1991.tb03867.x","article-title":"Pemphigus and bullous pemphigoid due to drugs.","volume":"30","author":"Ruocco","year":"1991","journal-title":"Int J Dermatol"},{"issue":"1","key":"doi200031r25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archderm.1976.01630250039012","article-title":"Occurrence of bullous pemphigoid after furosemide therapy.","volume":"112","author":"Fellner","year":"1976","journal-title":"Arch Dermatol"},{"issue":"3","key":"doi200031r26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2133.2000.03389.x","article-title":"Pemphigoid nodularis associated with nifedipine.","volume":"142","author":"Ameen","year":"2000","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi200031r27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1440-0960.2001.00497.x","article-title":"Bullous pemphigoid induced by cephalexin.","volume":"42","author":"Czechowicz","year":"2001","journal-title":"Australas J Dermatol"},{"issue":"12","key":"doi200031r28","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/ijd.13705","article-title":"Linagliptin-induced bullous pemphigoid.","volume":"56","author":"Esposito","year":"2017","journal-title":"Int J Dermatol"},{"issue":"2","key":"doi200031r29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaad.2010.02.032","article-title":"A case of bullous pemphigoid induced by aspirin.","volume":"65","author":"Durdu","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi200031r30","first-page":"562","article-title":"Furosemide-induced bullous pemphigoid: case report and review of literature.","volume":"5","author":"Lee","year":"2006","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"doi200031r31","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s11606-016-3679-1","article-title":"Drug-induced bullous pemphigoid.","volume":"31","author":"Kanahara","year":"2016","journal-title":"J Gen Intern Med"},{"key":"doi200031r32","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2011.5180","article-title":"Rosuvastatin-induced pemphigoid.","author":"Murad","year":"2012","journal-title":"BMJ Case Rep"},{"issue":"3","key":"doi200031r33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study.","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"15","key":"doi200031r34","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"doi200031r37","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"doi200031r38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis.","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"issue":"3","key":"doi200031r40","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/archderm.1996.03890270044006","article-title":"Drugs associated with bullous pemphigoid. a case-control study.","volume":"132","author":"Bastuji-Garin","year":"1996","journal-title":"Arch Dermatol"},{"issue":"6","key":"doi200031r41","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland.","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"doi200031r42","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2169\/internalmedicine.49.3346","article-title":"Bullous pemphigoid and percutaneous endoscopic gastrostomy.","volume":"49","author":"Nozu","year":"2010","journal-title":"Intern Med"},{"issue":"4","key":"doi200031r43","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population.","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi200031r44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000480498","article-title":"Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid.","volume":"233","author":"Schaffer","year":"2017","journal-title":"Dermatology"},{"issue":"2","key":"doi200031r45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjd.15195","article-title":"The association between drugs and bullous pemphigoid.","volume":"176","author":"Tan","year":"2017","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi200031r46","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study.","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"6","key":"doi200031r47","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jaad.2018.05.030","article-title":"Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case-control study.","volume":"79","author":"Varpuluoma","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi200031r48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaad.2019.02.017","article-title":"Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: a case-control study.","volume":"81","author":"Varpuluoma","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"doi200031r49","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.15195","article-title":"Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: a nationwide, population-based, cohort study in Taiwan.","volume":"47","author":"Hung","year":"2020","journal-title":"J Dermatol"},{"issue":"1","key":"doi200031r50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial.","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"doi200031r51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-4632.2009.03839.x","article-title":"Medication history of a series of patients with bullous pemphigoid from northern Greece\u2014observations and discussion.","volume":"48","author":"Patsatsi","year":"2009","journal-title":"Int J Dermatol"},{"issue":"4","key":"doi200031r53","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/0968-0004(93)90022-F","article-title":"Autoimmune disease and molecular mimicry: an hypothesis.","volume":"18","author":"Baum","year":"1993","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"doi200031r54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/pgs.09.11","article-title":"Immunogenetics of drug-induced skin blistering disorders. part I: perspective.","volume":"10","author":"Bowman","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"4","key":"doi200031r55","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0738-081X(93)90148-6","article-title":"Blistering eruptions caused by drugs: commentary.","volume":"11","author":"Ruocco","year":"1993","journal-title":"Clin Dermatol"},{"issue":"3","key":"doi200031r56","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0738-081X(98)00010-8","article-title":"Drug-induced pemphigus.","volume":"16","author":"Brenner","year":"1998","journal-title":"Clin Dermatol"},{"key":"doi200031r52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000104189","volume-title":"Drug Hypersensitivity","author":"Park","year":"2007"},{"key":"doi200031r57","volume-title":"Adverse Drug Reactions and the Skin","author":"Breathnach","year":"1992"},{"key":"doi200031r35","doi-asserted-by":"crossref","unstructured":"Liu? S-D, Chen? W-T, Chi C-C. Association between drug use and bullous pemphigoid. Published 2018. Accessed January 6, 2020. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42018115041","DOI":"10.1001\/jamadermatol.2020.1587"},{"key":"doi200031r36","unstructured":"Wells? GA, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Published 2019. Accessed February 1, 2020. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"doi200031r39","doi-asserted-by":"crossref","unstructured":"Higgins? J, Thomas J, Chandler? J, eds. Cochrane handbook for systematic reviews of interventions, version 6.0. Updated July 2019.Cochrane, 2019. Accessed May 10, 2020. http:\/\/www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2767250\/jamadermatology_liu_2020_oi_200031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T01:41:22Z","timestamp":1597282882000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2767250"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.1587","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}